Karolinska Development's Strategic Move for Modus Therapeutics
In a significant move for growth and development, Karolinska Development AB, a prominent player in the Nordic life sciences sector, announced that its portfolio company, Modus Therapeutics, is undertaking a fully secured rights issue worth SEK 28.3 million. This funding aims to support the advanced clinical journey of sevuparin, a drug candidate targeting chronic kidney disease complicated by anemia.
A Crucial Step in Drug Development
On June 26, Modus Therapeutics, which is listed on the Nasdaq First North Growth Market, revealed its decision to launch this rights issue. The initiative will bring in SEK 28.3 million, prior to any associated costs, upon full subscription. This move is subject to the green light from an extraordinary general meeting set for July 29.
Financing the Clinical Journey
The primary objective of securing this capital is to expedite the ongoing clinical phase II study of sevuparin. The funds will also ensure that operations are maintained throughout 2026, allowing the company to meet significant milestones in its developmental timeline.
Backing by Key Shareholders
Key stakeholders, including Karolinska Development, influential figures like Hans Wigzell and Anders Bladh, have made substantial free subscription commitments—totaling SEK 17.7 million—which covers approximately 62.7% of the rights issue. The remaining 37.3% is backed by external underwriting commitments, showcasing robust confidence in Modus Therapeutics' strategy and future prospects.
Confidence in Challenging Markets
Viktor Drvota, the CEO of Karolinska Development, expressed optimism about the successful rights issue amidst challenging market conditions. He stated, “Securing a fully subscribed rights issue is a clear indicator of strength for Modus Therapeutics and its clinical strategy. Our significant ownership and support reinforce our belief in the company’s potential to make significant advancements in sevuparin’s development.”
Karolinska Development's Commitment
Karolinska Development holds a substantial 66% stake in Modus Therapeutics, reflecting its deep commitment to nurturing innovative advancements within the life sciences landscape. The parent company consistently seeks to identify and support breakthrough medical innovations crafted by passionate entrepreneurs.
Focus on Innovative Treatment Solutions
The strategic direction of Karolinska Development emphasizes not only financial investment but also building a framework that fosters innovation. With access to world-renowned medical advancements from institutions like the Karolinska Institutet, it aims to cultivate companies around cutting-edge scientists, bolstered by adept management teams and financing from specialized global investors.
Growing Portfolio of Life-Saving Innovations
Currently, Karolinska Development boasts a portfolio encompassing eleven dynamic companies dedicated to addressing serious health challenges with innovative treatments. Guided by an entrepreneurial team recognized for their expertise as company builders, the objective remains clear: turning innovative concepts into life-changing products for patients while ensuring shareholder value.
Contact Information for Further Inquiries
For further insights or inquiries regarding Karolinska Development's activities and strategic initiatives involving Modus Therapeutics, please reach out to:
Viktor Drvota, CEO
Phone: +46 73 982 52 02
Email: viktor.drvota@karolinskadevelopment.com
Johan Dighed, General Counsel and Deputy CEO
Phone: +46 70 207 48 26
Email: johan.dighed@karolinskadevelopment.com
Frequently Asked Questions
What is the purpose of the SEK 28.3 million rights issue?
The funds will primarily finance the clinical development of sevuparin for chronic kidney disease and support operations until the end of 2026.
Who are the major shareholders backing this rights issue?
Key shareholders include Karolinska Development, Hans Wigzell, and Anders Bladh, who together have committed SEK 17.7 million, covering a significant part of the rights issue.
What are the expected outcomes of the rights issue?
The rights issue aims to successfully develop and advance the clinical phase of sevuparin, ultimately contributing to better treatment options for patients with chronic kidney disease.
How does Karolinska Development support its portfolio companies?
Karolinska Development provides financial investment, access to medical innovations, and builds supportive frameworks around innovative scientists and management teams to enhance success rates.
What is Modus Therapeutics’ main focus?
Modus Therapeutics is focused on developing sevuparin, a drug candidate aimed at treating chronic kidney disease with anemia, signifying a critical area in medical need.
